Septerna (NASDAQ:SEPN) 주식

SEPTERNA INC

Septerna

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Septerna Inc

News

GPUS

Hyperscale Data Plans To Resume Bitcoin Mining Operations At One Of Its Two Montana Sites On Or Around June 10, 2025

Quarterhill (TSX:<a class="ticker" href="https://www.benzinga.com/stock/QTRH#TSX">QTRH</a>) reported quarterly losses of $(0.07) per share. This is a 75 percent decrease over losses of $(0.04) per share from the same period last year. The company reported $33.89 million in sales this quarter. This is a 2.89 percent decrease over sales of $34.90 million the same period last year.

Earnings

TSX:QTRH

Quarterhill Q1 EPS $(0.07) Down From $(0.04) YoY, Sales $33.89M Down From $34.90M YoY

Needham analyst Laura Martin reiterates Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Buy and maintains $88.5 price target.

Price Target

Reiteration

Analyst Ratings

ROKU

Needham Reiterates Buy on Roku, Maintains $88.5 Price Target

Fiscal Year 2026 Outlook
Based on current visibility, backlog of existing orders and business trends, the Company issued the following targets for fiscal 2026. Net sales are expected to be in the range of $2.825 billion to $2.975 billion. Adjusted EBITDA is expected to be in the range of $850 million to $910 million. Capital expenditures are expected to be approximately $275 million.

Guidance

Advanced Drainage Systems Sees FY2026 Sales $2.825B-$2.975B Vs. $3.07B Est

NACCO Industries&#xAE; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NC#NYSE">NC</a>) announced today that its Board of Directors declared a regular quarterly cash dividend of 25.25 cents per share, which represents an 11% increase compared to the prior quarterly dividend rate of 22.75 cents per share. The dividend is payable on both the Class A and Class B Common Stock, and will be paid June 16, 2025 to stockholders of record at the close of business on May 30, 2025. The new dividend is equal to an annual rate of $1.01 per share, up 10 cents from the prior annual rate of $0.91 per share. This represents NACCO's seventh consecutive annual dividend increase since the dividend was reset following the spin-off of Hamilton Beach Brands Holding Company in September 2017. NACCO and its predecessor companies have paid quarterly cash dividends to stockholders since 1956.

Dividends

NACCO Industries Raises Quarterly Cash Dividend 11% From $0.23 To $0.25 Per Share

JP Morgan analyst Samik Chatterjee downgrades Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) from Overweight to Neutral.

Downgrades

LAZR

JP Morgan Downgrades Luminar Technologies to Neutral

On the Acquired podcast, Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang made a frank admission: if he were 30 years of age again, he would not start his own company. Despite NVIDIA's record-breaking success, Huang revealed his feelings about the <a href="https://www.benzinga.com/markets/25/05/45243129/nvidia-ceo-jensen-huang-says-losing-access-to-chinas-potential-50-billion-ai-market-would-be-a-tremendous-loss">challenging parts</a> of the journey.
What Happened: When asked what kind of company he would create if given another chance, Huang responded, "I wouldn't do it."
"Building a company and building Nvidia turned out to have been a million times harder than any of us expected it to be. And at the time, if we realized the pain and suffering and just how vulnerable you're going to feel and the challenges that you're going to endure, the embarrassment and the shame, and the list of all the things that go wrong—I don't think anybody would start a company. Nobody in their right mind would do it," Huang added. 
See Also: <a href="https://www.benzinga.com/media/25/05/45426637/nvidia-ceo-jensen-huang-expected-to-unveil-new-ai-alliances-at-computex-2025-as-geopolitical-pressures-persist-over-tech-sector">Nvidia CEO Jensen Huang Expected To Unveil New AI Alliances At Computex 2025 As Geopolitical Pressures Persist Over Tech Sector</a>
Why It Matters: Huang noted that most founders achieve success because they underestimate the difficulty at the beginning. "You have to get yourself to believe that it's not that hard because it's way harder than you think…Taking all of my knowledge now—I go back, and I said I'm going to endure that whole journey again, I think it's too much. It is just too much.&#8221;
He also highlighted the importance of a robust support network. "You need the unwavering support of the people around you… I'm pretty sure that almost every successful company and entrepreneurs that have gone through some difficult challenges had that support system around them."
Despite these challenges, Huang's company continues to make waves, with Nvidia projected to <a href="https://www.benzinga.com/news/large-cap/25/05/45414265/nvidia-climbs-on-saudi-ai-investments-analyst-estimates-15-billion-to-20-billion-in-revenue">generate billions in revenue</a> from newly announced investments from Saudi Arabia. On Tuesday, President Donald Trump praised Huang for controlling "99% of the chip market" during the <a href="https://www.benzinga.com/markets/equities/25/05/45398595/trump-praises-nvidia-ceo-jensen-huang-at-saudi-summit-tim-cook-isnt-here-but-you-are-controlling-99-of-the-chip-market-thats-not-easy-to-beat">U.S.-Saudi Investment Forum</a>, spotlighting the company's planned $500 billion investment in U.S. artificial intelligence infrastructure.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="NVIDIA CEO Jensen Huang" width="500" height="281" src="https://www.youtube.com/embed/y6NfxiemvHg?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45430137/trump-had-a-problem-with-tim-cook-president-says-he-told-apple-ceo-i-dont-want-you-building-in-india-amid-tariff-concerns-and-production-shift-from-china">Trump Had A &#8216;Little Problem&#8217; With Apple CEO Tim Cook, Says &#8216;I Don&#8217;t Want You Building In India&#8217;</a></li>
</ul>
Image Via Shutterstock

Success Stories

NVDA

Jensen Huang Says He Wouldn't Start Nvidia Again If He Were 30, Calling The Journey 'Too Much' Despite the Company's Massive Success

BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.42) by 21.43 percent. This is a 88.21 percent increase over losses of $(2.80) per share from the same period last year.

Earnings Beats

PHGE

BiomX Q1 EPS $(0.33) Beats $(0.42) Estimate

Advanced Drainage Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>) reported quarterly earnings of $1.03 per share which missed the analyst consensus estimate of $1.10 by 6.36 percent. This is a 16.26 percent decrease over earnings of $1.23 per share from the same period last year. The company reported quarterly sales of $615.76 million which missed the analyst consensus estimate of $653.22 million by 5.73 percent. This is a 5.82 percent decrease over sales of $653.84 million the same period last year.

Earnings Misses

Advanced Drainage Systems Q4 Adj. EPS $1.03 Misses $1.10 Estimate, Sales $615.76M Miss $653.22M Estimate

Jefferies analyst Alejandro Demichelis upgrades Petrobras Brasileiro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) from Hold to Buy and announces $15.3 price target.

Upgrades

Jefferies Upgrades Petrobras Brasileiro to Buy, Announces $15.3 Price Target

BABA

UPDATE: Alibaba Reported A 76% Drop in Free Cash Flow to $516M in Q1 2025 Due to Higher Cloud Infrastructure Spending

DA Davidson analyst Keegan Cox assumes Hasbro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) with a Neutral rating and maintains Price Target of $75.

Initiation

DA Davidson Assumes Hasbro at Neutral, Maintains Price Target of $75

Net income attributable to Deere &amp; Company for fiscal 2025 is forecasted to be in a range of $4.75&nbsp;billion to $5.50 billion.
 &nbsp;

Deere & Co Expects FY25 Net Income Of $4.75B-$5.50B

Needham analyst Mayank Tandon maintains Endava (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVA#NYSE">DAVA</a>) with a Buy and lowers the price target from $22 to $18.

DAVA

Needham Maintains Buy on Endava, Lowers Price Target to $18

Deere Q2 EPS $6.64 Beats $5.59 Estimate, Sales $12.76B Beat $10.79B Estimate

Biotech

Health Care

Financing

Offerings

General

AURA

Aura Biosciences Has Launched An Underwritten Public Offering Of Shares And Accompanying Warrants, Details Undisclosed

As Of March 31, 2025, Aura Biosciences Had Cash And Cash Equivalents And Marketable Securities Of $128M, Sufficient To Fund Its Operations Into 2H Of 2026

Aura Biosciences Q1 2025 EPS $(0.55) Misses $(0.48) Estimate

TSLA

Bloomberg Reported Emirates In Talks With Elon Musk's Spacex To Get Starlink On Flights

DA Davidson analyst Michael Baker assumes Mattel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) with a Buy rating and maintains Price Target of $30.

DA Davidson Assumes Mattel at Buy, Maintains Price Target of $30

Press Releases

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Legal

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors

SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm

Septerna to Present at TD Cowen 45th Annual Health Care Conference

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN

SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Comments

Septerna

뉴스

파트너 / 기고자

벤징가 글로벌